5:14 PM
 | 
May 25, 2010
 |  BC Extra  |  Company News

Vivitrol receives Priority Review

FDA accepted for filing and granted Priority Review to an sNDA from Alkermes Inc. (NASDAQ:ALKS)...

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >